Neil Goldsmith

Serial entrepreneur with broad experience of the life science sector. Founder or otherwise instrumental in the early development of fourteen ventures in five countries (UK, Sweden, Denmark, Switzerland, USA) over thirty years. Of these six achieved stock market listings, five trade sale exits and four ultimately failed (some count twice). From 2004-2017 co-founder and CEO of Evolva SA, a synthetic biology pioneer, taking it from start-up to a listing on the Swiss exchange, with multiple product launches. Currently active with RiverStone (synbio for human health), Unibio (production of protein from methane), Sundew (treating water borne diseases) & Alentis (treatment of fibrosis).